

# Registration is now open for Oligonucleotide Therapeutics and Delivery 2021

*SMI reports: Registration is now open for the Oligonucleotide Therapeutics and Delivery Conference, which will convene in London on 22nd and 23rd September.*

LONDON, LONDON BRIDGE , UNITED KINGDOM, April 19, 2021

/EINPresswire.com/ -- Established on the success of our RNA [Therapeutics](#) series, we look forward to welcoming you at [Oligonucleotide Therapeutics and Delivery](#) to join the conversation around maximizing the potential of oligo-based treatments.

Bringing together leading representatives of pharmaceutical, biotechnology and academic institutions, the 2-day conference will provide first-hand information on the latest clinical trial candidates and a platform for exchanging ideas for tackling the biggest challenge: DELIVERY.

Plus, an interactive half day pre-conference workshop:

Target Discovery for RNA Therapeutics

Workshop Leader: Martin Akerman, Chief Technology Officer, Envisagenics

Registration is live on the website and an early bird saving of £200 will be applied to bookings made before 28th May 2021: [www.oligonucleotide.co.uk/einpr1a](http://www.oligonucleotide.co.uk/einpr1a)

Highlights will include:

- Gain first-hand insight into oligonucleotide therapy clinical success of the latest developments for novel agents
- Listen to case studies presenting the latest candidates undergoing pre-clinical and clinical research
- Deepen your understanding of crucial delivery methods and available platforms for non-



hepatocytic delivery

- Explore the chemistry of oligonucleotide therapeutics and examine novel applications of antisense oligonucleotides in the AstraZeneca Deep Dive
- Engage in the latest innovations of oligonucleotide therapeutics with insights into immunochemotherapeutics, ocular indications and Duchenne Muscular Dystrophy

The event brochure with the agenda and speaker line-up is available to download from the website; those interested in attending can register at: [www.oligonucleotide.co.uk/einpr1a](http://www.oligonucleotide.co.uk/einpr1a)

Proudly Sponsored by ChemGenes | Genscript | Tosoh Bioscience

For media queries please contact Jinna Sidhu at [hsidhu@smi-online.co.uk](mailto:hsidhu@smi-online.co.uk) or call +44 (0)20 7827 6088

About SMi Group:

Established since 1993, the SMi Group is a global event-production company that specializes in Business-to-Business Conferences, Workshops, Masterclasses and online Communities. We create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical industries. We pride ourselves on having access to the world's most forward-thinking opinion leaders and visionaries, allowing us to bring our communities together to Learn, Engage, Share and Network. More information can be found at <http://www.smi-online.co.uk>

Jinna Sidhu  
SMi Group  
02078276088  
[email us here](#)

---

This press release can be viewed online at: <https://www.einpresswire.com/article/538804488>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2021 IPD Group, Inc. All Right Reserved.